The pharmaceutical industry in Serbia can offer the state its experience and expertise in order to drive technological advancement in areas such as healthcare digitalisation and the application of artificial intelligence
At the FIC Pharmaceutical Industry Committee, we believe that one of the key advances in Serbia’s pharmaceutical industry is the state’s increasing investment in improving the availability of new therapeutic options. In practice, this means greater access to medicines and improved healthcare for patients in Serbia. However, these funds still aren’t sufficient to fully meet the needs of patients, and we are not yet at the level of medicine availability seen in the European Union, though we are certainly on track to achieving that.
Globally, we live in an exceptionally challenging environment when it comes to medicine supply. We are witnessing global shortages of some extremely important medicines. Economic crises, wars, labour shortages and rising production costs are just a few of the reasons for potential supply disruptions. Given all these factors, the role of the pharmaceutical industry in Serbia is becoming increasingly significant. I am confident that the industry, in cooperation with the state, will work to ensure the most stable medicine supply possible.
To maintain and improve the availability of innovative and generic medicines in Serbia, we need to focus on a few key steps: long-term savings through the use of efficient and modern therapies with preventative measures; analysis of the effectiveness of therapy; accelerating procedures for registering and introducing as many innovative and generic medicines as possible to the Drug Lists in Serbia. An active dialogue between institutions, companies and experts is an essential condition for any discussion about the progress of healthcare today.
Easier Access to Healthcare for All
We aim to improve dialogue and foster better, more efficient cooperation with state institutions, ensuring that every citizen has faster and easier access to healthcare
We’ve made progress in Serbia in terms of building partnerships and improving dialogue with the Ministry of Health, the National Health Insurance Fund and the Medicines and Medical Devices Agency, to ensure the provision of the most efficient and effective healthcare to all citizens.
I would also like to highlight the fact that the pharmaceutical industry in Serbia can offer the state its experience and expertise in order to drive technological advancements in areas such as healthcare digitalisation and the application of artificial intelligence. Digitalisation and the use of artificial intelligence bring many benefits to healthcare, from improving diagnostics and personalising medicine to suit patients’ individual needs, to speeding up administrative processes that become more efficient, freeing up healthcare workers to focus on direct patient care. The fast processing and sharing of medical data enhances analytics and the evaluation of the effectiveness of different therapeutic options. All these changes together make the healthcare system more efficient, precise and accessible, where the pharmaceutical industry can assist in various partnership projects with state institutions.
This is why the FIC Pharmaceutical Industry Committee will be very active, as we see this moment as representing the right time to launch new ideas and new solutions.
We want to work to improve dialogue and establish more effective cooperation with state institutions, so that every citizen can have faster and easier access to healthcare.
